Indivior Plc (LON:INDV) target maintained at 370.00GBX, reported today by Numis
- Updated: September 25, 2016
Having a price of 311.40GBX, Indivior Plc (LON:INDV) traded -0.32% lower on the day. The last closing price is up 36.36% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. INDV has recorded a 50-day moving average of 315.92GBX and a two hundred day average of 229.17GBX. Volume of trade was down over the average, with 559,360 shares of INDV changing hands under the typical 2,343,710
Indivior Plc (LON:INDV) had its stock price target hold steady to 370.00GBX by Numis in a report released 9/26/2016. The latest price target suggests a potential upside of 0.19% from the company's most recent close.
On Monday August 22, 2016, Jefferies International released a statement on Indivior Plc (LON:INDV) upped the target price from 330.00GBX to 370.00GBX that suggested an upside of 0.13%.
With a market cap of 0 GBX, Indivior Plc has 52 week low of 126.60GBX and a 52 week high of 365.00GBX with a price-earnings ratio of 12.50 .
A total of 8 analysts have released a research note on INDV. Three analysts rating the company a strong buy, two brokerages rating the stock a buy, 2 brokerages rating the stock a hold, 1 brokerage rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of 3.32GBX.
Brief Synopsis On Indivior Plc (LON:INDV)
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company's treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia. Indivior's products, which are sold in over 40 countries, consist of Suboxone film (buprenorphine and naloxone), Suboxone tablet (buprenorphine and naloxone) and Subutex tablet (buprenorphine sublingual tablet), all of which are used to treat opioid dependence. Its Buprenorphine lifecycle includes Suboxone Tablet, Suboxone Film, Buprenorphine Monthly Depot and Oral Swallowable Capsule. Its overdose rescue product category includes Cocaine Esterase. Its alcohol use disorders product category includes Arbaclofen Placarbil. Its adjacency-schizophrenia product category includes Risperidone Monthly Depot.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.